Summit Therapeutics Inc.

Summit Therapeutics Inc. is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing oncology medicines. Its lead program is ivonescimab, a bispecific antibody licensed for development and commercialization across the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa.

9.87

9.87

— Summit Therapeutics Inc.
%
Ivonescimab development100% Clinical development of the lead bispecific antibody candidate for oncology indications.
Commercialization rights0% Rights to market and sell ivonescimab in licensed territories if approved.
Clinical trial operations0% Execution of late-stage oncology studies supporting regulatory submissions.
Supply and licensing collaboration0% Licensed access to drug substance and product supply through Akeso.

Summit’s direct customers are not traditional end-market buyers today; its business is centered on clinical development...

  • Oncology patientsprimary

    Patients with serious cancers who would receive ivonescimab if approved.

  • Physicians and cancer centersprimary

    Oncologists and treatment centers that prescribe and administer the therapy.

  • Government and commercial payorsprimary

    Reimbursement decision-makers that influence access and uptake.

  • Clinical trial sitessecondary

    Hospitals and research centers that enroll patients in Phase III studies.

  • Commercial partners and supplierssecondary

    Third parties involved in manufacturing, supply, and commercialization support.

Summit is headquartered in the United States, and most of its workforce is based there...

  • •Headquartered in the United States
  • •About 91% of employees are based in the United States
  • •Licensed territory covers North America, Europe, Japan, LATAM, MEA
  • •Akeso retains rights outside Summit’s licensed territory
  • •Clinical trials have enrolled patients in North America, Europe, and China

Summit’s strategy is centered on advancing ivonescimab through late-stage development and preparing for potential...

01
Complete late-stage development of ivonescimabshort-term

Clinical success is the main value driver for the company.

02
Prepare for commercialization in licensed territoriesshort-term

Approval would require sales, market access, and distribution capabilities.

03
Strengthen reimbursement and market access positioningmedium-term

Payor acceptance will influence adoption and launch economics.

04
Secure supply and manufacturing arrangementsmedium-term

Commercial launch depends on reliable drug substance and product supply.

Summit faces the typical risks of a late-stage biopharmaceutical company: clinical trial failure, regulatory delays,...

critical

Clinical development failure

Late-stage oncology trials may not replicate earlier results or meet endpoints.

Scope
ivonescimab Phase III program
Materiality
high
high

Regulatory approval risk

Marketing authorization depends on agency review of safety and efficacy data.

Scope
BLA and other filings in licensed territories
Materiality
high
high

Payor and reimbursement pressure

Government and commercial payors may challenge price and cost effectiveness.

Scope
Commercial launch and adoption
Materiality
high
high

Supply chain and manufacturing dependence

The company relies on third parties and Akeso for drug supply and product.

Scope
Clinical and commercial supply
Materiality
high
high

Single-product concentration

Most value is tied to one lead candidate and its oncology indications.

Scope
Corporate valuation and operating model
Materiality
high
Research and development expense estimation
Affects operating loss and comparability between quarters
Stock-based compensation
Affects reported operating expenses and equity dilution
License milestone and royalty obligations
Can create future liabilities and expense recognition timing issues
Commitments and supply arrangements
Affects liabilities, cash commitments, and launch economics

Century Therapeutics, Inc.

IPSC · Biological Products, (No Diagnostic Substances)

INTENSITY THERAPEUTICS, INC.

INTS · Biological Products, (No Diagnostic Substances)

Compass Therapeutics, Inc.

CMPX · Biological Products, (No Diagnostic Substances)

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

CELZ · Biological Products, (No Diagnostic Substances)

Climb Bio, Inc.

CLYM · Pharmaceutical Preparations

RAPT Therapeutics, Inc.

Pharmaceutical Preparations

: 29.4.2026